Mubadala cements cautious life sciences approach with $235m Evotec investment

Mubadala Investment Company agreed to acquire €200 million (US$235 million) worth of Hamburg-based Evotec shares in a private placement, giving the United Arab Emirates sovereign wealth fund a 5.6% stake in one of Germany's top life sciences firms.

Novo Holdings kicked in an additional €50 million (US$58.8 million) in the offering. But Novo is a longtime Evotec investor that brought its stake in the company up to 11% with the transaction, so the headline news here is Mubadala's increasing eagerness to play the biotech trade.

Mubadala CEO Khaldoon . . .

Continue Reading

Unlock this article instantly, along with the rest of our premium content, newsletters and data tables tracking investor and manager activity. Annual subscriptions get you the most bang for your buck, including access to Alternatives Watch Research articles and out Annual Investor Compendium.

Monthly subscriptions and discounted corporate plans for up to 100 members also available.

Sergio Barreto

Sergio Barreto is about 70% journalist, 30% tech geek. As an editor for The ABIS Group, he produces daily newsletters for leading healthcare and technology companies. With BMV Digital, he provides WordPress-based web developments services. Here at Alternatives Watch, he wears both hats - handling IT and occasionally writing about the intersection of alts, healthcare and tech.

Related Articles

Back to top button

Start Your Days in the Know

 

Get fresh alts intel in your inbox with our FREE newsletter!

You have Successfully Subscribed!